Reuters logo
BRIEF-MediciNova announces exploratory interim clinical outcomes data from clinical trial of MN-166 (ibudilast)
December 9, 2016 / 11:17 AM / in 10 months

BRIEF-MediciNova announces exploratory interim clinical outcomes data from clinical trial of MN-166 (ibudilast)

Dec 9 (Reuters) - MediciNova Inc

* MediciNova announces exploratory interim clinical outcomes data from clinical trial of MN-166 (ibudilast) in ALS presented at the 27th international symposium on ALS/MND in Dublin, Ireland

* MediciNova Inc says vital capacity (VC), a measure of respiratory function, and 3 MN-166 (ibudilast) was well tolerated

* MediciNova says statistically significant decreases in muscle strength 2 weeks after stopping MN-166 (ibudilast) for hip flexion, leg flexion, neck flexion Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below